Colin James Suckling

This inventor holds 7 USPTO granted patents and 1 published patent application, plus 2 CIPO patents and 3 EPO patents. Top assignees: University of Strathclyde, Imperial Chemical Industries Limited, University of Glasgow. Active years: 1990-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Colin James Suckling. Retrieved from https://idiyas.com/inventor/colin-james-suckling

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 7 (Patent Applications = 1)

% Patents Active = 85.7

CIPO Patents = 2 (Patent Applications = 3)

EPO Patents = 3 (Patent Applications = 1)

Average Co-Inventor Count = 3.4

ph-index = 2

Forward Citations = 25(Granted Patents)

Company Filing History:

6 out of 151

University of Strathclyde

patents

1 out of 3,840

Imperial Chemical Industries Limited

patents

1 out of 124

University of Glasgow

patents

where one patent can have more than one assignee

Years Active: 1990-2017

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9598386 - Immunomodulatory compounds (2017-03-21),

2. 8012967 - Minor groove binders (2011-09-06),

3. 7700765 - DNA minor groove binding compounds (2010-04-20),

4. 6849628 - Optically active compounds (2005-02-01),

5. 6500829 - Substantially pure diastereoisomers of tetrahydrofolate derivatives (2002-12-31),

6. 5063149 - Performing an enzyme-catalyzed reaction (1991-11-05),

7. 4959472 - Process for preparing substantially pure diastereoisomers of (1990-09-25),

Title: Colin James Suckling: Innovator in Immunomodulatory Compounds

Introduction

Colin James Suckling is a notable inventor based in Glasgow, GB. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that address inflammation-related diseases. With a total of 7 patents to his name, Suckling's work has had a meaningful impact on therapeutic approaches.

Latest Patents

Among his latest patents, Suckling has developed immunomodulatory compounds aimed at treating or preventing diseases associated with inflammation. This invention highlights the potential for new therapeutic strategies in managing inflammatory conditions. Additionally, he has created minor groove binders, which are compounds that bind to the minor groove of DNA, offering promising applications in genetic research and drug development.

Career Highlights

Colin James Suckling has worked with prestigious institutions such as the University of Strathclyde and Imperial Chemical Industries Limited. His experience in these organizations has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Some of his notable coworkers include Lilias Gilmour Rees and Abedawn I Khalaf. Their collaborative efforts have further advanced the research and development of innovative compounds.

Conclusion

Colin James Suckling's contributions to the field of medicinal chemistry through his patents and collaborations underscore his role as a significant innovator. His work continues to influence the development of new therapeutic strategies for managing inflammation-related diseases.

Profile summary based on public USPTO records.